Genevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio’s BARDA Award
12 Ottobre 2023 - 11:00PM
Genevant Sciences, a leading nucleic acid delivery company with
world-class platforms and a robust and expansive lipid nanoparticle
(LNP) patent portfolio, today announced the use of its LNP
technology in Gritstone bio’s (Nasdaq: GRTS) self-amplifying mRNA
(samRNA) vaccine candidate against COVID-19 in its CORAL program.
Gritstone was recently awarded a contract by the Biomedical
Advanced Research and Development Authority (BARDA) as part of
‘Project NextGen,’ an initiative by the U.S. Department of
Health and Human Services to advance a pipeline of new,
innovative vaccines and therapeutics providing broader and more
durable protection for COVID-19.
The BARDA award, received by Gritstone following
results from multiple Phase 1 studies of its COVID-19 vaccine
candidate, is for the conduct of a 10,000 participant, randomized
Phase 2b double-blinded study to compare the efficacy, safety, and
immunogenicity of Gritstone’s COVID-19 vaccine candidate with an
approved COVID-19 vaccine.
“We value our longstanding relationship with
Gritstone bio and congratulate the Gritstone team on receiving the
BARDA award,” said Pete Lutwyche, Ph.D., President and Chief
Executive Officer, Genevant Sciences Corporation. “As longtime
leaders in the field, we know that delivery is often the difference
in the success of nucleic acid-based medicines and we are thrilled
with the contribution of our LNP technology to Gritstone’s
achievement.”
About Genevant SciencesGenevant
Sciences is a leading nucleic acid delivery company with
world-class platforms, a robust and expansive lipid nanoparticle
(LNP) patent portfolio, and decades of experience and expertise in
nucleic acid drug delivery and development. The Company’s
scientists have pioneered LNP delivery of nucleic acids for over 20
years, and the Company’s LNP platform, which has been studied
across more than a dozen discrete product candidates and is the
delivery technology behind the first and only approved systemic
RNA-LNP product (patisiran), enables a wide array of RNA-based
applications, including vaccines, therapeutic protein production,
and gene editing. For more information, please visit
www.genevant.com.
Pete Zorn
President and Chief Legal Officer
Genevant Sciences, Inc.
245 Main Street, 2nd Floor
Cambridge, MA 02142
O: 1-617-500-0764
M: 1-781-941-6290
pete.zorn@genevant.com
Grafico Azioni Gritstone bio (NASDAQ:GRTS)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Gritstone bio (NASDAQ:GRTS)
Storico
Da Set 2023 a Set 2024